Investors see confidence in China slowly back in 2023; seeking China-Japan opportunities

19 April 2023

By Wang Fangqing

Biotech investors are cautiously optimistic about opportunities in China in 2023, and they are looking for novel or value-added assets only, said investors at the CMAC conference held in Suzhou in earlier this month.

“There still is some bubble left in China’s biotech industry and we don’t want to make drastic moves before the bubble is gone,” said Zhao Qun, partner at Suzhou-based venture capital Oriza. He said the company plans to make investments in the next one or two years.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK